Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 7
2004 3
2006 5
2007 5
2008 5
2009 3
2010 13
2011 6
2012 11
2013 16
2014 9
2015 6
2016 7
2017 8
2018 5
2019 6
2020 4
2021 1
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for martha nance
Search for Earthea Nance instead (2 results)
Huntington disease.
Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Bates GP, et al. Among authors: nance m. Nat Rev Dis Primers. 2015 Apr 23;1:15005. doi: 10.1038/nrdp.2015.5. Nat Rev Dis Primers. 2015. PMID: 27188817 Review.
Genetics of Huntington disease.
Nance MA. Nance MA. Handb Clin Neurol. 2017;144:3-14. doi: 10.1016/B978-0-12-801893-4.00001-8. Handb Clin Neurol. 2017. PMID: 28947123 Review.
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Providing genetic testing and genetic counseling for Parkinson's disease to the community.
Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Beck JC, Naito A, Hall A, Chan AK, Casaceli CJ, Marder K, Nance M, Schwarzschild MA, Simuni T, Wills AM, Alcalay RN; Parkinson’s Foundation and Parkinson's Study Group (PSG). Cook L, et al. Among authors: nance m. Genet Med. 2023 Oct;25(10):100907. doi: 10.1016/j.gim.2023.100907. Epub 2023 Jun 8. Genet Med. 2023. PMID: 37302021 Free article. Clinical Trial.
Genetic testing in inherited ataxias.
Nance MA. Nance MA. Semin Pediatr Neurol. 2003 Sep;10(3):223-31. doi: 10.1016/s1071-9091(03)00031-7. Semin Pediatr Neurol. 2003. PMID: 14653410 Review.
Tools for communicating risk for Parkinson's disease.
Cook L, Schulze J, Uhlmann WR, Verbrugge J, Marder K, Lee AJ, Wang Y, Alcalay RN, Nance M, Beck JC. Cook L, et al. Among authors: nance m. NPJ Parkinsons Dis. 2022 Nov 29;8(1):164. doi: 10.1038/s41531-022-00432-6. NPJ Parkinsons Dis. 2022. PMID: 36446806 Free PMC article.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
Therapy in Huntington's disease: where are we?
Nance MA. Nance MA. Curr Neurol Neurosci Rep. 2012 Aug;12(4):359-66. doi: 10.1007/s11910-012-0277-4. Curr Neurol Neurosci Rep. 2012. PMID: 22544535 Review.
117 results